Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Entyvio
Pharma
Takeda eyes upcoming launches as Vyvanse generics hit lingers
The company has three key phase 3 readouts this year, which it hopes will contribute to long-term growth despite a flat outlook for 2025.
Zoey Becker
May 8, 2025 10:36am
JPM25: Takeda touts 6 pipeline assets with big sales potential
Jan 15, 2025 3:17pm
Takeda's Entyvio keeps its strong IBD position despite threats
Jul 31, 2024 4:43pm
The top 10 pharma drug ad spenders for 2023
Jun 3, 2024 3:00am
Takeda plots $900M restructuring plan as profits plummet
May 9, 2024 12:00pm
Takeda treads water despite loss of exclusivity on Vyvanse
Feb 1, 2024 1:56pm
